Seegene, Inc. Logo

Seegene, Inc.

096530.KQ

(0.0)
Stock Price

22.050,00 KRW

1.88% ROA

2.24% ROE

49.49x PER

Market Cap.

1.147.146.121.600,00 KRW

9.39% DER

3.23% Yield

6.05% NPM

Seegene, Inc. Stock Analysis

Seegene, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Seegene, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Seegene, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Seegene, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Seegene, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Seegene, Inc. Revenue
Year Revenue Growth
2012 51.712.796.630
2013 58.992.832.190 12.34%
2014 64.410.877.290 8.41%
2015 65.136.597.357 1.11%
2016 73.693.589.458 11.61%
2017 88.919.576.022 17.12%
2018 102.264.773.396 13.05%
2019 121.953.286.875 16.14%
2020 1.125.215.548.220 89.16%
2021 1.370.833.012.026 17.92%
2022 853.561.091.243 -60.6%
2023 339.710.314.360 -151.26%
2023 367.375.048.980 7.53%
2024 400.558.495.852 8.28%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Seegene, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2012 1.583.672.559
2013 2.802.836.000 43.5%
2014 2.812.020.000 0.33%
2015 1.737.082.790 -61.88%
2016 2.383.047.000 27.11%
2017 12.603.169.906 81.09%
2018 10.276.955.173 -22.64%
2019 9.646.956.452 -6.53%
2020 25.947.767.317 62.82%
2021 75.581.866.000 65.67%
2022 94.397.711.545 19.93%
2023 70.112.716.000 -34.64%
2023 72.013.100.445 2.64%
2024 63.712.403.328 -13.03%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Seegene, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 20.803.273.506
2013 4.405.357.000 -372.23%
2014 5.293.368.000 16.78%
2015 5.791.553.000 8.6%
2016 6.442.549.000 10.1%
2017 7.275.853.000 11.45%
2018 8.327.900.000 12.63%
2019 7.766.132.000 -7.23%
2020 18.646.737.000 58.35%
2021 49.682.955.000 62.47%
2022 44.217.152.000 -12.36%
2023 23.250.184.000 -90.18%
2023 35.109.505.000 33.78%
2024 258.792.300.000 86.43%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Seegene, Inc. EBITDA
Year EBITDA Growth
2012 -1.795.244.452
2013 17.322.815.100 110.36%
2014 16.780.251.069 -3.23%
2015 14.672.671.970 -14.36%
2016 16.638.651.409 11.82%
2017 13.867.944.930 -19.98%
2018 18.007.446.510 22.99%
2019 32.600.022.240 44.76%
2020 693.633.853.450 95.3%
2021 702.916.865.400 1.32%
2022 238.848.508.650 -194.29%
2023 27.421.268.120 -771.03%
2023 35.656.111.240 23.1%
2024 67.156.440.316 46.91%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Seegene, Inc. Gross Profit
Year Gross Profit Growth
2012 35.102.043.744
2013 43.779.677.900 19.82%
2014 46.829.420.160 6.51%
2015 41.038.686.584 -14.11%
2016 46.292.858.304 11.35%
2017 55.716.356.630 16.91%
2018 60.280.476.975 7.57%
2019 71.680.634.599 15.9%
2020 842.718.034.933 91.49%
2021 1.058.731.595.184 20.4%
2022 466.148.388.052 -127.12%
2023 189.826.974.640 -145.56%
2023 180.071.653.852 -5.42%
2024 209.159.867.688 13.91%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Seegene, Inc. Net Profit
Year Net Profit Growth
2012 9.102.938.415
2013 9.572.517.860 4.91%
2014 9.141.388.090 -4.72%
2015 6.774.128.601 -34.95%
2016 7.122.595.582 4.89%
2017 3.186.975.045 -123.49%
2018 10.098.321.712 68.44%
2019 26.672.069.051 62.14%
2020 502.281.109.100 94.69%
2021 536.558.868.440 6.39%
2022 182.138.620.710 -194.59%
2023 -10.158.216.240 1893.02%
2023 669.011.750 1618.39%
2024 96.197.620.000 99.3%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Seegene, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 233
2013 195 -19.49%
2014 182 -7.14%
2015 132 -38.93%
2016 136 3.68%
2017 61 -122.95%
2018 194 68.56%
2019 513 62.18%
2020 9.662 94.69%
2021 10.358 6.72%
2022 3.586 -188.85%
2023 -216 1767.91%
2023 14 1635.71%
2024 2.084 99.33%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Seegene, Inc. Free Cashflow
Year Free Cashflow Growth
2012 1.083.453.997
2013 -4.132.957.580 126.21%
2014 -564.633.470 -631.97%
2015 -3.561.298.921 84.15%
2016 5.841.931.903 160.96%
2017 3.788.540.742 -54.2%
2018 10.045.435.131 62.29%
2019 27.856.673.342 63.94%
2020 207.889.214.589 86.6%
2021 267.912.711.734 22.4%
2022 246.557.252.861 -8.66%
2023 5.147.894.320 -4689.48%
2023 63.052.614.457 91.84%
2024 11.746.429.164 -436.78%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Seegene, Inc. Operating Cashflow
Year Operating Cashflow Growth
2012 3.672.940.358
2013 -2.893.225.780 226.95%
2014 6.777.155.700 142.69%
2015 4.104.835.654 -65.1%
2016 16.557.316.937 75.21%
2017 10.115.432.388 -63.68%
2018 14.009.661.695 27.8%
2019 32.643.051.696 57.08%
2020 383.157.253.783 91.48%
2021 334.024.477.480 -14.71%
2022 319.008.873.805 -4.71%
2023 10.567.795.310 -2918.69%
2023 94.932.061.457 88.87%
2024 20.072.122.297 -372.95%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Seegene, Inc. Capital Expenditure
Year Capital Expenditure Growth
2012 2.589.486.361
2013 1.239.731.800 -108.87%
2014 7.341.789.170 83.11%
2015 7.666.134.575 4.23%
2016 10.715.385.034 28.46%
2017 6.326.891.646 -69.36%
2018 3.964.226.564 -59.6%
2019 4.786.378.354 17.18%
2020 175.268.039.194 97.27%
2021 66.111.765.746 -165.11%
2022 72.451.620.944 8.75%
2023 5.419.900.990 -1236.77%
2023 31.879.447.000 83%
2024 8.325.693.133 -282.9%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Seegene, Inc. Equity
Year Equity Growth
2012 41.937.201.927
2013 84.445.180.120 50.34%
2014 94.834.881.570 10.96%
2015 129.441.923.201 26.74%
2016 142.230.026.743 8.99%
2017 117.260.713.288 -21.29%
2018 128.356.436.777 8.64%
2019 152.825.652.523 16.01%
2020 646.405.927.786 76.36%
2021 1.083.596.367.747 40.35%
2022 1.150.278.974.828 5.8%
2023 1.059.734.780.290 -8.54%
2023 1.030.398.975.557 -2.85%
2024 1.043.182.874.706 1.23%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Seegene, Inc. Assets
Year Assets Growth
2012 83.615.649.293
2013 129.038.996.280 35.2%
2014 138.453.263.280 6.8%
2015 196.629.946.553 29.59%
2016 209.971.252.163 6.35%
2017 158.057.994.090 -32.84%
2018 165.618.170.917 4.56%
2019 195.715.540.240 15.38%
2020 1.094.574.623.631 82.12%
2021 1.489.718.580.570 26.52%
2022 1.390.777.557.476 -7.11%
2023 1.276.020.668.850 -8.99%
2023 1.251.451.913.635 -1.96%
2024 1.267.641.673.971 1.28%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Seegene, Inc. Liabilities
Year Liabilities Growth
2012 41.678.447.366
2013 44.593.816.160 6.54%
2014 43.618.381.710 -2.24%
2015 67.188.023.352 35.08%
2016 67.741.225.420 0.82%
2017 40.797.280.802 -66.04%
2018 37.261.734.140 -9.49%
2019 42.889.887.717 13.12%
2020 448.168.695.845 90.43%
2021 406.122.212.823 -10.35%
2022 240.498.582.648 -68.87%
2023 216.285.888.550 -11.19%
2023 221.052.938.078 2.16%
2024 224.458.799.265 1.52%

Seegene, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
8287.15
Net Income per Share
501.1
Price to Earning Ratio
49.49x
Price To Sales Ratio
3x
POCF Ratio
13.6
PFCF Ratio
22.09
Price to Book Ratio
1.1
EV to Sales
2.8
EV Over EBITDA
22.92
EV to Operating CashFlow
12.72
EV to FreeCashFlow
20.62
Earnings Yield
0.02
FreeCashFlow Yield
0.05
Market Cap
1.147,15 Bil.
Enterprise Value
1.070,89 Bil.
Graham Number
15941.41
Graham NetNet
9807.15

Income Statement Metrics

Net Income per Share
501.1
Income Quality
3.64
ROE
0.02
Return On Assets
0.02
Return On Capital Employed
-0.02
Net Income per EBT
1.11
EBT Per Ebit
-0.94
Ebit per Revenue
-0.06
Effective Tax Rate
0.1

Margins

Sales, General, & Administrative to Revenue
0.39
Research & Developement to Revenue
0.18
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.5
Operating Profit Margin
-0.06
Pretax Profit Margin
0.05
Net Profit Margin
0.06

Dividends

Dividend Yield
0.03
Dividend Yield %
3.23
Payout Ratio
1.6
Dividend Per Share
800

Operating Metrics

Operating Cashflow per Share
1823.63
Free CashFlow per Share
1125.12
Capex to Operating CashFlow
0.38
Capex to Revenue
0.08
Capex to Depreciation
0.47
Return on Invested Capital
-0.02
Return on Tangible Assets
0.02
Days Sales Outstanding
108.63
Days Payables Outstanding
30.89
Days of Inventory on Hand
237.13
Receivables Turnover
3.36
Payables Turnover
11.82
Inventory Turnover
1.54
Capex per Share
698.51

Balance Sheet

Cash per Share
11.483,24
Book Value per Share
22.602,29
Tangible Book Value per Share
21781.96
Shareholders Equity per Share
22539.78
Interest Debt per Share
2217.4
Debt to Equity
0.09
Debt to Assets
0.08
Net Debt to EBITDA
-1.63
Current Ratio
5.03
Tangible Asset Value
1.005,32 Bil.
Net Current Asset Value
548,23 Bil.
Invested Capital
968486609132
Working Capital
618,97 Bil.
Intangibles to Total Assets
0.03
Average Receivables
107,59 Bil.
Average Payables
15,68 Bil.
Average Inventory
126385661125.5
Debt to Market Cap
0.09

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Seegene, Inc. Dividends
Year Dividends Growth
2023 800
2024 600 -33.33%

Seegene, Inc. Profile

About Seegene, Inc.

Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection products; drug resistance products; Magicplex sepsis real-time test for the detection and identification of sepsis causing pathogens; and meningitis detection products. The company also provides other products for the detection of six SNPs in factor II, factor V, and MTHFR genes; BRAF mutation characteristic for papillary thyroid carcinoma from samples of thyroid tissue, fine needle aspiration biopsy, H&E slides, and paraffin-embedded tissues; Apolipoprotein E genotypes; and BCR/ABL fusion gene from blood and whole bone marrow. In addition, it offers PCR machines; vial cap management systems; nucleic acid extraction systems; automated liquid handling workstations from nucleic acid extraction to PCR setup; and real-time PCR detection systems. Seegene, Inc. was founded in 2000 and is headquartered in Seoul, South Korea.

CEO
Dr. Jong-Yoon Chun
Employee
63
Address
Taewon Building
Seoul, 05548

Seegene, Inc. Executives & BODs

Seegene, Inc. Executives & BODs
# Name Age
1 Jong-Gi Cheon
Vice President and Chairman of Seegene Medical Foundation
70
2 Dr. Jong-Yoon Chun
Founder, Chief Executive Officer, Chief Technology Officer & Director
70
3 Mr. Jin-Soo Choi
Executive Vice President & Director
70
4 Dr. Richard S. Creager Ph.D.
Chief Executive Officer of Seegene Technologies
70

Seegene, Inc. Competitors

Celltrion, Inc. Logo
Celltrion, Inc.

068270.KS

(2.0)
Samsung Biologics Co.,Ltd. Logo
Samsung Biologics Co.,Ltd.

207940.KS

(1.8)
Medy-Tox Inc. Logo
Medy-Tox Inc.

086900.KQ

(0.0)
Hanmi Pharm. Co., Ltd. Logo
Hanmi Pharm. Co., Ltd.

128940.KS

(1.0)